Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.62 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.60 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5068476 | 0.90 | CYP4A11 (0.68) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL9725219 | 0.87 | CYP4A11 (0.67) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL24835147 | 0.85 | CYP4A11 (0.57) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL70185 | 0.85 | CYP4A11 (0.75) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL9825792 | 0.83 | CYP4A11 (0.64) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL4642635 | 0.83 | CA12 (0.56) | HRH3ALDH1A1HPGDNPC1GAA | |
| SCHEMBL24835214 | 0.83 | CYP4A11 (0.58) | CYP4A11CYP4F2LOXL2HRH3ALDH1A1 | |
| SCHEMBL5118351 | 0.81 | CYP4A11 (0.66) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL5067508 | 0.81 | LOXL2 (0.61) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD | |
| SCHEMBL5065491 | 0.80 | HPGD (0.55) | CYP4A11CYP4F2LOXL2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815907-B2 | Quaternary ammonium compounds useful as muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2014-08-26 | — | — | US | disclosed |
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281489-A1 | QUATERNARY AMMONIUM COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM5, CHRM1 | CYP4A11 1391/4885CYP4F2 3210/4885LOXL2 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.